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Background : Follicular patterned thyroid nodules with incomplete nuclear features of papil-
lary thyroid carcinoma (FTN-INPTCs) are difficult to diagnose, and their biological behavior
and association with follicular variants of PTC (FVPTCs) have not yet been established. The
aim of this study is to determine immunohistochemical and molecular characteristics of FTN-
INPTCs. Methods : We investigated immunohistochemical features (galectin-3, HBME-1,
CK19, fibronectin-1, CITED1), BRAF V600E mutation and RASSF1A promoter methylation
status in 30 FTN-INPTC cases, along with 26 FVPTCs, 21 follicular adenomas (FAs) and 14
nodular hyperplasias (NHs). Results : Expression of galectin-3, HBME-1, CK19 and CITED1
was significantly higher in FTN-INPTCs than in FAs or NHs, but expression of galectin-3, CK19
and fibronectin-1 was lower in FTN-INPTCs than in FVPTCs. The BRAF V600E mutation was
not detected in the benign nodules or FTN-INPTCs, whereas 57% of FVPTCs had the muta-
tion. RASSF1A promoter methylation was higher in FTN-INPTCs than in benign nodules but
there was no difference between FTN-INPTCs and FVPTCs. Conclusions : Our results rep-
resent the borderline immunohistochemical and molecular characteristics of FTN-INPTC. We
conclude that FTN-INPTC is an intermediate lesion between a benign nodule and a FVPTC,
and that it is pathogenetically related to FVPTC. 
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Follicular variant of papillary thyroid carcinoma (FVPTC) is
a special subtype of papillary thyroid carcinoma (PTC). It resem-
bles follicular neoplasm and is almost exclusively composed of
follicles without papillary structures. Thus, its diagnosis is based
on the characteristic nuclear features of PTC, including enlarge-
ment, ground glass appearance, grooves, and pseudoinclusions.1
However, atypical cells whose nuclei have a clear chromatin
pattern, membrane irregularity, grooves, or even pseudo-inclu-
sions are occasionally observed in benign thyroid nodules such
as nodular hyperplasia (NH) or follicular adenoma (FA). These
features resemble the characteristic nuclei of papillary carcinoma
but the degree of nuclear atypia is incomplete for the definite
diagnosis of FVPTC. The diagnostic difficulty of this “follicu-
lar patterned thyroid nodule with incomplete nuclear features
of papillary thyroid carcinoma (FTN-INPTC)” has been men-
tioned previously.2 The use of the diagnostic term “well differ-
entiated tumor of uncertain malignant potential (WDTUMP)”
was suggested by the Chernobyl Pathologists Group to desig-
nate an encapsulated and non-invasive tumor with equivocal or
questionable nuclear features of PTC, emphasizing the poten-
tial for malignant transformation of this lesion.3,4
PTCs have critical genetic alterations associated with their de-
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velopment, such as RET/PTC or NTRK1 rearrangements, and
BRAF V600E or RAS mutations.5 The BRAF V600E mutation
is found in 29-83% of PTCs,6,7 making it the most common ge-
netic event in PTC. In addition, a few epigenetic changes have
been identified in PTCs, including silencing of RASSF1A (RAS
association domain family protein 1A). RASSF1A is a tumor
suppressor gene inhibiting cell cycle progression,5 which is reg-
ulated by promoter hypermethylation. It is silenced in 20-62%
of PTCs and it has been reported that its silencing and the BRAF
mutation are mutually exclusive.8,9 Interestingly, RASSF1A pro-
moter methylation is also found in follicular adenoma, suggest-
ing that epigenetic inactivation of RASSF1A is an early step in
thyroid tumorigenesis.
In this study, we investigated immunohistochemically the
expression of several markers in FTN-INPTCs. These included
galectin-3,10,11 HBME-1,4,12,13 cytokeratin 19 (CK19),13,14 fibro-
nectin-1,15 and CITED1,15 which have been reported to be mark-
ers of PTC. We also examined BRAF V600E mutation and
RASSF1A promoter methylation in FTN-INPTCs. By compar-
ing these results with those of FVPTCs, FAs and NHs, we tried
to determine the histological features, immunohistochemical
and molecular characteristics of this atypical follicular lesion. 
MATERIALS AND METHODS
Tissue specimens and histopathologic evaluation
Ninety-one cases of surgically resected thyroid lesions includ-
ing 26 FVPTCs, 30 FTN-INPTCs, 21 FAs and 14 NHs were
collected from files in the Department of Pathology, Seoul Na-
tional University Bundang Hospital from 2004 to 2007. Twen-
ty-two of the patients were male (24%) and 69 female (76%)
with a mean age of 49±12.6 years (mean±standard deviation;
range, 17-80 years).
Pathologic information was obtained from hematoxylin and
eosin (H-E)-stained sections. FTN-INPTC was defined as fol-
lows: a follicle-forming nodule whose nuclei have similar but
incomplete and not identical features to PTC, such as chromatin
clearing, grooves, membrane irregularity, overlapping, and pseu-
doinclusions. The following clinicopathologic variables were re-
corded in FTN-INPTCs: distribution of nuclear atypia (diffuse
or focal), overall features of FTN-INPTC i.e. lesion (FA or NH)
in which incomplete nuclear features of PTC are observed, and
presence of concurrent PTC in the surrounding thyroid parenchy-
ma. FVPTC cases were defined as follicle-forming tumors hav-
ing the characteristic nuclear features of PTC without any visi-
ble papillary architecture, irrespective of encapsulation. All cases
were independently reviewed and confirmed by two endocrine
pathologists.
Immunohistochemistry and interpretation
Representative paraffin blocks were selected for immunohis-
tochemistry. Four micron-thick sections were deparaffinized,
rehydrated in a series of alcohols, and processed with a DAKO-
Envision detection kit (DakoCytomation, Carpinteria, CA, USA).
Antigen was retrieved in a microwave oven for 15 min in 10
mmol/L citrate buffer pH 6.0. Endogenous peroxidase activity
was blocked with a 3% H2O2-methanol solution, and the slides
were incubated in 10% normal goat serum for 10 min to prevent
nonspecific staining. They were then incubated for 1 h at room
temperature with an appropriately diluted primary antibody.
The following antibodies were used: galectin-3 (9C4; 1:600;
Novocastra, UK), HBME-1 (HBME-1; 1:100; DakoCytoma-
tion), CK19 (RCK108; 1:150; DakoCytomation), fibronectin-
1 (polyclonal; 1:2,000; DakoCytomation), CITED1 (polyclon-
al; 1:50; Abcam, UK). Thereafter, the sections were incubated
with horseradish peroxidase-labeled polymer conjugated with
secondary antibodies for 30 min. Diaminobenzidine was used as
a chromogen, and the sections were counterstained with Mayer’s
hematoxylin. As a negative control, non-immune serum was su-
bstituted for the primary antibody.
Galectin-3 and CITED1 expression was both nuclear and/or
cytoplasmic. HBME-1 was expressed in the cytoplasm and cell
membrane with occasional luminal accentuation. CK19 expres-
sion was cytoplasmic with membranous accentuation. Fibro-
nectin-1 was expressed in the cytoplasm.
The expression of markers was classified as follows: negative,
no staining or staining in less than 10% of the cells of a lesion;
positive, staining in more than 10% of the cells. Staining of 10-
50% of the cells was defined as focal positive, and staining of
more than 50% was defined as diffuse positive. 
Detection of the BRAF mutation
Genomic DNA was extracted from all cases and sequencing
was possible in 77 cases, including 32 benign nodules, 24 FTN-
INPTCs, and 21 FVPTCs. Briefly, representative areas were ma-
rked with 4 micron-thick H-E stained sections as guides. Then,
the marked areas were matched with de-waxed but unstained
10 micron-thick sections. The tumor areas were dissected from
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the unstained slides and transferred into Eppendorf tubes. After
dissection, the blocks were cut into 4 micron sections for H-E
staining to confirm tumor continuity. All the samples were then
digested with proteinase K for more than 24 h at 56℃, and
DNA was isolated from the digested tissue using a General Bio-
systems Tissue SV mini kit (General Biosystems, Seoul, Korea).
We amplified BRAF exon 15 by the polymerase chain reaction
(PCR) using primers: forward, 5′-GCTTGCTCTGATAGGA-
AAATGAG-3′, reverse, 5′-GATACTCAGCAGCATCTCA-
GG-3′. PCR conditions were: 95℃ for 5 min, 40 cycles at 94
℃ for 20 s, 56℃ for 20 s, 72℃ for 20 s, and 72℃ for 10 min.
We sequenced the purified PCR products in an MJ Research
PTC-225 Peltier Thermal Cycler using ABI PRISM� BigDyeTM
Terminator Cycle Sequencing Kits and AmpliTaq� DNA poly-
merase (FS enzyme) (Applied Biosystems, Foster city, CA, USA).
Single-pass sequencing was performed on each template using
the forward primer. The fluorescence-labeled fragments obtained
were purified from unincorporated terminators by ethanol pre-
cipitation, resuspended in distilled water and subjected to elec-
trophoresis in an ABI 3730xl sequencer (Applied Biosystems).
Real-time quantitative methylation-specific PCR (MSP)
for RASSF1A
The genomic DNA was converted with sodium bisulfite as
described previously,16 and the DNA was purified using a QIA-
amp viral RNA mini kit (Qiagen, Valencia, CA, USA). For real-
time quantitative MSP, we used the MethyLight assay.17 The PCR
amplification was performed using TaqMan� 1,000 RXN Gold
supplied with the Buffer A Pack (Applied Biosystems), in a total
volume of 30 mL containing 10 mL DNA, 3.5 mmol/L MgCl2,
3.0 mL 10×buffer, 200 mmol/L each of dNTP, 0.3 nmol/L each
of forward and reverse primers, 0.3 nmol/L TaqMan probe, and
0.5 mL AmpliTaq Gold DNA polymerase (5 U/mL). Real-time
PCR reactions were followed with an ABI Prism 7,700 Sequence
Detection System (Applied Biosystems). The primers and probe
designed to specifically amplify bisulfite-converted DNA in the
promoter region of the methylated version of RASSF1A gene
were used: forward 5′-GCG TTG AAG TCG GGG TTC-3′;
reverse 5′-CCC GTA CTT CGC TAA CTT TAA ACG-3′; probe
6FAM-5′-ACA AAC GCG AAC CGA ACG AAA CCA-3′-
TAMRA, and primers and probe for the ALU-based Methy-
Light control reaction were also used, to normalize data.17 The
percentage of fully methylated DNA at a RASSF1A gene was
calculated by dividing the RASSF1A:ALU ratio of a sample by
the RASSF1A:ALU ratio of SssI-treated sperm DNA and mul-
tiplying by 100.18 The calculated values were expressed as per-
cent of methylated reference (PMR). For the analysis, lesions were
considered to be methylated when their PMR >4, and unmethy-
lated when their PMR ≤4.
Statistical analysis
Statistical analysis was performed with SPSS software (version
11.0, SPSS Inc., Chicago, IL, USA). Chi-square or Fisher’s exact
tests were used when comparing frequencies between groups.
All numerical data are expressed as means±SD, and differences
between means of groups were compared by ANOVA test. Prob-




Nineteen (63.3%) of the 30 FTN-INPTCs arose on a back-
ground of NH, and 11 cases (36.7%) on FAs (Fig. 1). Of the 19
FTN-INPTCs on an NH background, eight (42.1%) showed
diffuse, incomplete PTC-type nuclear changes, and 11 (57.9%)
had focal nuclear changes. In contrast, of the 11 FTN-INPTCs
on an FA background, that is, the encapsulated FTN-INPTCs,
three (27.3%) showed the nuclear changes focally, and eight
(72.7%) showed diffuse nuclear changes. Of the 30 FTN-INPTCs,
preoperative aspiration cytology was performed in 12 cases. Three
cases were diagnosed as benign nodules, 5 as follicular neoplasms,
3 as indeterminate and one as ‘suspicious for papillary carcino-
ma’. Resected specimens were diagnosed as nodular hyperplasia
in 12 cases, follicular adenoma in 8, atypical adenoma in 2,
WDTUMP in 4 and FVPTC in the remaining 4 cases. Sixteen
(53.3%) of the 30 FTN-INPTCs had concurrent PTC, compared
with only two of the NHs and none of the FAs (p<0.001, Table
1). The ages of the patients tended to increase in the order: benign
nodule, FTN-INPTC, and FVPTC (p=0.077, Table 1). 
Expression of PTC-related markers
Immunohistochemical expression of galectin-3, HBME-1,
CK19, fibronectin-1, and CITED1 differed significantly between
the groups. Most of these markers were not expressed in the be-
nign nodules, or, in a few cases, showed only focal reactivity
(Table 2). Exceptionally, CK19 was expressed in five benign nod-
ules (14.3%, two cases of FA and three cases of NH), and the two
FA cases showed diffuse expression of CK19. There was no sig-
nificant difference between FTN-INPTCs with an NH back-
ground and those with an FA background in the expression of
galectin-3 (52.6% vs 45.5%), CK19 (47.4% vs 27.3%), HBME-
1 (100% vs 81.8%) or CITED-1 (78.9% vs 72.7%). Fibronec-
tin-1 was expressed only in FTN-INPTCs with an FA backgro-
und (36.4% vs 0%; p=0.005), and there was no significant di-
fference in the expression of the markers between FTN-INPTCs
with focal atypia and those with diffuse atypia. The expression
of galectin-3, HBME-1, CK19, and CITED1 was significantly
higher in FTN-INPTCs than in benign nodules (Table 2). 
Comparing FTN-INPTCs with FVPTCs, the expression of
galectin-3, CK19, and fibronectin-1 was significantly higher
in FVPTCs (Table 2; Fig. 2, 3). All of the FVPTCs showed dif-
fuse and strong expression of galectin-3, whereas 8 (53.3%) of
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Fig. 1. A case of follicular patterned thyroid nodule with incomplete nuclear features of papillary carcinoma on a background of nodular
hyperplasia (A, B). In a low magnification, this nodule has no capsule and shows marked size variation of follicles, resembling nodular
hyperplasia (A). High power magnification reveals nuclear clearing and grooves, not sufficient for the diagnosis of papillary thyroid carci-
noma (B). Another case of follicular patterned thyroid nodule with incomplete nuclear features of papillary carcinoma on a background of
follicular adenoma (C, D). In a low magnification, this nodule has a well developed capsule and is composed of similar sized follicles,
resembling follicular adenoma (C). High power magnification reveals nuclei with imperfect nuclear features of papillary thyroid carcinoma,
showing minor degree of nuclear clearing and grooves (D). 
A B
C D
Benign nodulea FTN-INPTC FVPTC
(n=35) (n=30) (n=26)
Age (year) 45.7±13.5 50.3±12.4 52.8±10.8
Male:Female 11:24 8:22 3:23
Presence of papillary 2 (5.7%)b 16 (53.3%)b NA
carcinoma in other area
aBenign nodules consist of 21 follicular adenomas and 14 nodular
hyperplasias; bp<0.001, benign nodule vs FTN-INPTC.
FTN-INPTC, follicular patterned thyroid nodule with incomplete nuclear
features of PTC; FVPTC, follicular variant of papillary thyroid carcinoma;
NA, not applicable.
Table 1. Clinicopathologic features of benign nodules, FTN-
INPTCs, and FVPTCs
15 galectin-3 positive FTN-INPTCs revealed diffuse but rela-
tively week expression (p<0.001). While FVPTCs showed dif-
fuse and strong staining to CK19 in a high proportion, FTN-
INPTCs revealed only focal and weak staining (p<0.001). When
comparing combined expression of these markers, all FVPTCs
were positive for both galectin-3 and CK19, whereas six (20.0%)
of 30 FTN-INPTCs were positive for both of them (p<0.001).
And all of the six FTN-INPTCs revealed focal staining to CK19.
Twenty (76.9%) of the 26 FVPTCs showed co-expression of
galectin-3, CK 19 and fibronectin-1, while only two (6.7%) of
the 30 FTN-INPTCs revealed their co-expression (p<0.001).
There was no significant difference in HBME-1 and CITED1
expression between the two groups, despite some different pat-
terns of expression: HBME-1 was diffusely expressed in all the
FVPTC cases, whereas half of the FTN-INPTCs showed focal po-
sitivity for HBME-1, and the other half showed diffuse but inc-
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RASSF1A PMR
Benign nodule FTN-INPTC FVPTC
(n=35) (n=30) (n=26)
0-1 2 0 0
1-3 8 1 4
3-4 3 3 0
4-5 6 2 2
5-10 6 9 4
10-50 9 11 14
>50 1 4 2
Methylation positive 22 (62.9%) 26 (86.7%) 22 (84.6%)
(PMR>4)
FTN-INPTC, follicular patterned thyroid nodule with incomplete nuclear
features of PTC; FVPTC, follicular variant of papillary thyroid carcinoma;
PMR, percent of methylated reference.
Table 3. The distribution of RASSF1A PMR values in benign no-
dules, FTN-INPTCs, and FVPTCs
Immunohistochemical




Galectin-3 1 (2.9%)a 15 (50.0%)a,d 26 (100%)d
Diffuse:focal 0:1 8:7 26:0
HBME-1 2 (5.7%)a 28 (93.3%)a,e 26 (100%)e
Diffuse:focal 0:2 14:14 26:0
CK19 5 (14.3%)b 12 (40.0%)b,d 26 (100%)d
Diffuse:focal 2:3 0:12 21:5
Fibronectin-1 0 (0%)c 4 (13.3%)c,d 20 (76.9%)d
Diffuse:focal 0:0 0:4 12:8
CITED1 3 (8.6%)a 23 (76.7%)a,f 18 (69.2%)f
Diffuse:focal 0:3 6:17 7:11
ap<0.001; bp=0.027; cp=0.258, benign nodule vs FTN-INPTC; dp<0.001;
ep=0.668; fP=0.531, FTN-INPTC vs FVPTC.
FTN-INPTC, follicular patterned thyroid nodule with incomplete nuclear
features of PTC; FVPTC, follicular variant of papillary thyroid carcinoma.
Table 2. Immunohistochemical differences between benign no-
dules, FTN-INPTCs, and FVPTCs
Fig. 2. A case of follicular patterned thyroid nodule with incomplete nuclear features of papillary thyroid carcinoma. Follicles contain irreg-
ular and clear nuclei resembling papillary carcinoma-type nuclear changes (A). The cells show focal expression of galectin-3 (B), HBME-
1 (C), CK19 (D), and fibronectin-1 (E). There is weak cytoplasmic and nuclear staining for CITED1 (F).
A B C
D E F
omplete expression along the cytoplasmic membrane. CITED1
was expressed in a relatively high proportion of both FTN-
INPTCs and FVPTCs (76.7% vs 69.2%).
BRAF mutation and RASSF1A promoter methylation
The BRAF V600E mutation was not found in any of the cases
of benign nodules and FTN-INPTCs, but 12 (57.1%) of the 21
FVPTC harbored the BRAF V600E mutation.
The methylation rate of the RASSF1A promoter was signifi-
cantly higher in FTN-INPTCs than in benign nodules (86.7%
vs 62.9%; p=0.029; Table 3). However, there was no signifi-
cant difference between FTN-INPTCs and FVPTCs, and in both
groups there was a high rate of methylation in the RASSF1A
promoter region (86.7% and 84.6%, respectively).
DISCUSSION
FTN-INPTC has been a subject of debate because of its poten-
tial for malignant transformation to PTC and several ambiguous
aspects. A wide spectrum of intra- or interobserver variation in
the diagnosis of FTN-INPTC has also been suggested,19 and
sometimes fixation artifacts seem to contribute to the morpho-
logical finding of PTC-like nuclei. Due to these complicating
factors, FTN-INPTC has occasionally been overdiagnosed as
FVPTC, despite incomplete nuclear changes, or underdiagnosed
as a benign nodule including FA or NH, particularly in cases
with focal nuclear atypia. FTN-INPTC still poses the diagnostic
problems for many pathologists as to whether it should be report-
ed as benign, borderline, or malignancy such as FVPTC.
In encapsulated follicular lesions with incomplete nuclear fea-
tures of PTC, the terms ‘follicular adenoma’ or ‘WDTUMP’ have
been used.1-3 However, incomplete nuclear features of PTC are
also found in non-encapsulated benign nodules, such as NHs
or Hashimoto thyroiditis.4,20,21 Fusco et al. reported that poorly
developed PTC-type nuclear changes were observed focally or
diffusely in NHs and the RET/PTC rearrangement could be de-
tected in these areas.21 Other authors reported PTCs within hy-
perplastic nodules,22 suggesting that some NHs are precursors
of well-differentiated carcinomas. On the other hand, coexisting
PTCs are well-documented in Hashimoto thyroiditis.23 In addi-
tion, the frequent detection of galectin-3, HBME-1, and cyclin
D1 expression, and of the RET/PTC rearrangement in PTC-type
pale nuclei implies that these atypical lesions are predisposed to
malignancy.24,25 Therefore, we selected both encapsulated and
non-encapsulated follicular lesions with incomplete nuclear fea-
tures of PTC, and divided them into two groups: FTN-INPTC
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Fig. 3. A control case of follicular variant of papillary carcinoma (A). In this case, galectin-3 (B), HBME-1 (C) and CK19 (D) show diffuse




with overall features of NH (non-encapsulated) or FTN-INPTC
with overall features of FA (encapsulated). Cases of Hashimoto
thyroiditis were excluded for several reasons; first, the sizes of
the atypical foci containing PTC-type nuclear changes are usu-
ally too small to obtain sufficient tissue for analysis. Second, they
contain a lot of intrinsic biotin that limits the reliability of the
immunohistochemical results. Lastly, the presence of lympho-
cytes in Hashimoto thyroiditis would confuse interpretation of
the methylation status of the lesion of interest.
Our results represent the borderline morphologic, immuno-
histochemical, and molecular characteristics of FTN-INPTC.
Expression of galectin-3, CK19, HBME-1 and CITED1 was
significantly higher in FTN-INPTCs than in benign nodules.
Immunoexpression of galectin-3 and CK19 was not only sig-
nificantly higher in FVPTCs than in FTN-INPTCs, but also
more diffuse and intense. Expression of HBME-1 was incom-
plete in FTN-INPTCs, although it was highly expressed in both
FVPTCs and FTN-INPTCs. Because results from the combina-
tion of these markers have been reported to be helpful in the
differential diagnosis of PTC,13,26 we compared combined expres-
sion of galectin-3, CK19 and fibronectin-1 in FVPTC and FTN-
INPTCs. While most of the FVPTC showed co-expression of
them, only a few cases of FTN-INPTCs showed their co-exex-
pression. Our immnohistochemical results seem to illustrate the
general borderline features of FTN-INPTCs. They are also consis-
tent with previous reports that have suggested that WDTUMP
and non-encapsulated FTN-INPTC are intermediate lesions be-
tween malignancy and benign nodules.4,11,15,27 We found no dif-
ference between the immunohistochemical findings for FTN-
INPTCs with focal nuclear changes and those with diffuse nucle-
ar changes, and the expression of markers was generally confined
to areas with PTC-type nuclear changes. Previous workers have
also demonstrated that thyroid nodules with foci showing PTC-
like nuclear change are positive for these markers only in cells
with PTC-like nuclear atypia.27,28
None of our 24 FTN-INPTC cases had the BRAF V600E mu-
tation (vs 57.1% of FVPTCs), but RASSF1A promoter methyla-
tion was as frequent in FTN-INPTCs as in FVPTCs (86.7% and
84.6%, respectively). These findings are consistent with the recent
report that the BRAF mutation is not present in WDTUMPs,
i.e. the encapsulated form of FTN-INPTC.22 On the other hand,
in studies of RAS mutations and the RET/PTC rearrangement,
WDTUMPs and non-encapsulated FTN-INPTCs were found
to be intermediate between benign nodules and carcinoma.21,28
Interestingly, RET activation closely parallels the morphological
changes; in other words, the molecular alterations are restricted
to areas featuring PTC-like nuclei. The absence of the BRAF
V600E mutation and the high frequency of RASSF1A promoter
methylation in our FTN-INPTC cases suggest that the BRAF
mutation acts in the later stage of malignant transformation to
PTC, whereas RASSF1A promoter methylation is an early event.
Recent data support this hypothesis by showing that RASSF1A
promoter methylation is present in both benign and malignant
thyroid tumors, and that the BRAF mutation is restricted in
PTCs and anaplastic carcinomas.29
The BRAF V600E mutation rate has been reported to be low
in FVTPCs, being 32% at most.30 Our FVPTC cases had a high-
er BRAF mutation rate (57.1%), which may partially reflect ge-
ographical factors since the BRAF mutation is common in Asian
populations.7
In our study, concurrent PTC was more frequent in FTN-
INPTCs compared to benign nodules (53.3% vs 5.7%; p<
0.001). This finding suggests that FTN-INPTC may arise from
the thyroid gland predisposed to develop PTC and indicate the
possibility of a coexisting PTC elsewhere in the thyroid gland.
To sum up, FTN-INPTC showed intermediate characteris-
tics between the FVPTC and the benign nodule immunohisto-
chemically. Moreover, RASSF1A methylation was significantly
more frequent in FTN-INPTCs than in benign nodules, and the
BRAF mutation was not observed in FTN-INPTCs. Therefore,
FTN-INPTC should be distinguished from FVPTC or benign
nodules. Although an appropriate diagnostic term for FTN-
INPTC should be proposed, the term “WDTUMP” may be pro-
visionally used for these cases irrespective of encapsulation sta-
tus. Our immunohistochemical and molecular findings seem
to reinforce the ambiguous nature of FTN-INPTCs; however,
they suggest that the incomplete PTC-type nuclear changes
observed by light microscopy are not artifacts but point to the
potential for transformation into PTCs and that FTN-INPTCs
are pathogenetically related to FVPTCs.
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